<code id='2127483C51'></code><style id='2127483C51'></style>
    • <acronym id='2127483C51'></acronym>
      <center id='2127483C51'><center id='2127483C51'><tfoot id='2127483C51'></tfoot></center><abbr id='2127483C51'><dir id='2127483C51'><tfoot id='2127483C51'></tfoot><noframes id='2127483C51'>

    • <optgroup id='2127483C51'><strike id='2127483C51'><sup id='2127483C51'></sup></strike><code id='2127483C51'></code></optgroup>
        1. <b id='2127483C51'><label id='2127483C51'><select id='2127483C51'><dt id='2127483C51'><span id='2127483C51'></span></dt></select></label></b><u id='2127483C51'></u>
          <i id='2127483C51'><strike id='2127483C51'><tt id='2127483C51'><pre id='2127483C51'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:comprehensive    Page View:85597
          Glaxo Smith Kline
          Akira Suemori/AP

          A few years ago, Vijay Pande, then a professor at Stanford who was using computer science to understand biology, was deciding whether to leave full-time academic work to become a venture capitalist. He turned to Andrew Ng, another Stanford professor who had joined Google Brain and later the Chinese search firm Baidu.

          “The things that we dreamed about five or 10 years ago were happening now,” Pande recalled Ng telling him. “The question was, do you want to be a part of it? Or do you want to write another paper?”

          advertisement

          Pande decided to become a venture capitalist. The result, he told an audience at a STAT event in San Francisco last week, is that, whereas he managed about $1 million to $2 million in research as a top academic, he now works at the fabled Silicon Valley firm Andreessen Horowitz, which invests $100 million a year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy
          FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

          PeterMarks,theFDA'stopregulatorofgenetherapies(right),speakswithSTAT'sAdamFeuersteininSanFrancisco.S

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          JPM 2024: Nvidia claims we're in biological revolution. Are we?

          SipaviaAPImagesSANFRANCISCO—Thesmallhotelmeetingroomwaspackedlikearushhoursubway.Bankersindarksuitsw